secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hoth Therapeutics, Inc. (HOTH)
CIK:        0001711786
Form:       8-K
Filed at:   2025-06-24T23:59:59+00:00
Accession:  0001213900-25-057233
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hoth Therapeutics reports 100% efficacy in Phase 2a of HT-001 for EGFRI skin toxicities
--------------------------------------------------------------------------------

- Phase 2a CLEER-001 study: 100% of patients achieved primary endpoint; 66% reported reduced pain/itching.
- All patients maintained EGFR inhibitor dosage while on HT-001, preserving cancer treatment.
- Preclinical data showed 56% reduction in hair loss and 58% reduction in facial lesions with preventive HT-001.
- HT-001 uses 505(b)(2) pathway; IND open; NDA submission targeted for 2030.
- No FDA-approved therapy exists for EGFRI-induced cutaneous toxicities; HT-001 seeks first-in-market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711786/000121390025057233/0001213900-25-057233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711786/000121390025057233/ea0246748-8k_hoth.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-057233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer